ArticleMicrobial biotechnology2026
Expanding the Genetic Toolkit of Pichia kudriavzevii E1 for Enhanced Mycoprotein Production.
Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pichia kudriavzevii is gaining attention as a non-conventional yeast with significant industrial potential, owing to its robust tolerance to low pH and diverse process-related stresses. However, the lack of a reliable episomal expression system and the scarcity of well-characterized promoters currently impede predictable gene expression and modular metabolic engineering in this workhorse. Here, we report development of the stable episomal expression vector for P. kudriavzevii E1. This was achieved through identification of a functional autonomously replicating sequence from the endogenous genome, guided by the established host-vector GC compatibility workflow. Leveraging this episomal platform, we then constructed an endogenous promoter library for P. kudriavzevii E1 via transcriptomic sequencing data analysis. Among the characterized promoters, the endogenous PkTDH3 promoter exhibited the highest activity. Notably, PkTDH3 demonstrated more stable and sustained expression compared to the strong promoter ScTDH3 from Saccharomyces cerevisiae, underscoring the value of establishing native promoter resources for P. kudriavzevii. Furthermore, we expanded the strength range of the promoter library by engineering the upstream activating sequence of PkTDH3 through random mutagenesis. As a proof of concept, the developed promoter library was employed to construct P. kudriavzevii mutants with elevated protein content, demonstrating the utility of this integrated genetic toolkit for strain engineering in P. kudriavzevii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.